EA200300040A1 - 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов - Google Patents

1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов

Info

Publication number
EA200300040A1
EA200300040A1 EA200300040A EA200300040A EA200300040A1 EA 200300040 A1 EA200300040 A1 EA 200300040A1 EA 200300040 A EA200300040 A EA 200300040A EA 200300040 A EA200300040 A EA 200300040A EA 200300040 A1 EA200300040 A1 EA 200300040A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antagonists
nicotinic receptors
neuronal nicotinic
cyclohexanes
aminoalkyl
Prior art date
Application number
EA200300040A
Other languages
English (en)
Other versions
EA006067B1 (ru
Inventor
Кристофер Грахам Рафаэль Парсонс
Войцех Даныш
Маркус Гольд
Иварс Калвиньш
Валерьянс Каусс
Айгарс Йиргенсонс
Original Assignee
Мерц Фарма Гмбх Унд Ко. Кгаа
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерц Фарма Гмбх Унд Ко. Кгаа filed Critical Мерц Фарма Гмбх Унд Ко. Кгаа
Publication of EA200300040A1 publication Critical patent/EA200300040A1/ru
Publication of EA006067B1 publication Critical patent/EA006067B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
    • C07C211/35—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Определенные 1-аминоалкилциклогексаны являются системно-активными антагонистами 5НТили нейрональных никотиновых рецепторов и полезны при ингибировании развития или облегчении состояний, являющихся результатом нарушений серотонинергической или никотинергической трансмиссии, что обеспечивает им широкий диапазон применимости при лечении CNS-нарушений, фармацевтические композиции для указанных целей и способы их получения, а также способ лечения состояний, которые облегчают применением антагониста 5НТили нейрональных никотиновых рецепторов.Отчет о международном поиске был опубликован 2002.04.25.
EA200300040A 2000-06-20 2001-06-19 Применение антагонистов 5-ht3 и нейрональных никотиновых рецепторов для лечения различных состояний EA006067B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59710200A 2000-06-20 2000-06-20
PCT/EP2001/006964 WO2001098253A2 (en) 2000-06-20 2001-06-19 1-amino-alkylcyclohexanes as 5-ht3 and neuronal nicotinicreceptor antagonists

Publications (2)

Publication Number Publication Date
EA200300040A1 true EA200300040A1 (ru) 2003-06-26
EA006067B1 EA006067B1 (ru) 2005-08-25

Family

ID=24390098

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300040A EA006067B1 (ru) 2000-06-20 2001-06-19 Применение антагонистов 5-ht3 и нейрональных никотиновых рецепторов для лечения различных состояний

Country Status (21)

Country Link
US (2) US20070105961A1 (ru)
EP (2) EP2277850A1 (ru)
JP (1) JP4159351B2 (ru)
KR (1) KR100570374B1 (ru)
CN (1) CN1307147C (ru)
AR (1) AR032756A1 (ru)
AU (2) AU2001281861B2 (ru)
CA (1) CA2410852C (ru)
CZ (1) CZ2003497A3 (ru)
EA (1) EA006067B1 (ru)
GE (1) GEP20053431B (ru)
HK (1) HK1076276A1 (ru)
HU (1) HUP0301551A3 (ru)
IL (2) IL153480A0 (ru)
MX (1) MXPA02012244A (ru)
NO (1) NO329491B1 (ru)
PL (1) PL359583A1 (ru)
TW (1) TW593223B (ru)
UA (1) UA74194C2 (ru)
WO (1) WO2001098253A2 (ru)
ZA (1) ZA200104187B (ru)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000540D0 (sv) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
GEP20094759B (en) 2002-10-24 2009-08-25 Merz Pharma Gmbh & Co Kgaa Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors
RS20050851A (sr) 2003-05-27 2008-04-04 Forest Laboratories Inc., Kombinacija antagonista nmda receptora i selektivnog inhibitora ponovnog preuzimanja serotonina za lečenje depresije i drugih poremećaja raspoloženja
CA2529674A1 (en) * 2003-07-28 2005-02-03 Merz Pharma Gmbh & Co. Kgaa The use of 1-amino-alkylcyclohexane compounds in the treatment of pain hypersensitivity
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
TW200531680A (en) * 2004-03-03 2005-10-01 Merz Pharma Gmbh & Co Kgaa Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease
CN101389315A (zh) * 2004-06-17 2009-03-18 莫茨药物股份两合公司 美金刚口服剂型即释制剂
AU2005325292A1 (en) * 2005-01-18 2006-07-27 University Of Florida Compositions and methods for inhibiting pain
PL2540297T3 (pl) 2008-11-19 2015-12-31 Forum Pharmaceuticals Inc Leczenie zaburzeń funkcji poznawczych(R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidem i jego farmaceutyczne dopuszczalnymi solami
TWI432188B (zh) * 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
US8399519B2 (en) 2008-12-19 2013-03-19 Merz Pharma Gmbh & Co. Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of mast cell mediated diseases
PL3029039T3 (pl) 2010-05-17 2018-04-30 Forum Pharmaceuticals Inc. Formulacje farmaceutyczne zawierające postacie krystaliczne jednowodnego chlorowodorku (R)-7-chloro-N-(chinuklidyn-3-ylo)benzo[b]tiofeno-2-karboksyamidu
AU2013259871A1 (en) 2012-05-08 2014-11-20 Forum Pharmaceuticals Inc. Methods of maintaining, treating or improving cognitive function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411955D0 (en) * 1994-06-15 1994-08-03 Merck Sharp & Dohme Therapeutic agents
US5886051A (en) * 1995-11-08 1999-03-23 University Of Florida Research Foundation, Inc. Methods and compositions for the treatment of neurodegeneration
ZA9610738B (en) * 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6436946B1 (en) * 1997-05-02 2002-08-20 Morris A. Mann Xanthine-containing compositions for oral administration and uses related thereto
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
US6071966A (en) * 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
TW593225B (en) * 1997-06-30 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane NMDA receptor antagonists
AR016212A1 (es) * 1998-04-28 2001-06-20 Astra Ab Uso de compuestos farmaceuticos que tienen una actividad antagonista de nmda para preparar un medicamento para el tratamiento del sindrome de intestino irritable (ibs), y composiciones farmaceuticas
US6139861A (en) * 1999-01-14 2000-10-31 Friedman; Mark Intraoral topical anti-inflammatory treatment for relief of migraine, tension-type headache, post-traumatic headache facial pain, and cervical-muscle spasm
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists

Also Published As

Publication number Publication date
CA2410852C (en) 2007-04-24
KR100570374B1 (ko) 2006-04-24
JP4159351B2 (ja) 2008-10-01
IL153480A0 (en) 2003-07-06
TW593223B (en) 2004-06-21
CZ2003497A3 (cs) 2004-08-18
UA74194C2 (ru) 2005-11-15
EP2277850A1 (en) 2011-01-26
GEP20053431B (en) 2005-01-25
HUP0301551A2 (hu) 2003-11-28
KR20030053475A (ko) 2003-06-28
IL153480A (en) 2007-08-19
CN1307147C (zh) 2007-03-28
AU2001281861B2 (en) 2006-08-17
EA006067B1 (ru) 2005-08-25
EP1303477A2 (en) 2003-04-23
WO2001098253A3 (en) 2002-04-25
ZA200104187B (en) 2002-11-22
WO2001098253A2 (en) 2001-12-27
PL359583A1 (en) 2004-08-23
CN1620419A (zh) 2005-05-25
CA2410852A1 (en) 2001-12-27
HK1076276A1 (en) 2006-01-13
HUP0301551A3 (en) 2005-04-28
US20070105961A1 (en) 2007-05-10
NO20026103D0 (no) 2002-12-19
MXPA02012244A (es) 2004-09-06
AR032756A1 (es) 2003-11-26
NO20026103L (no) 2003-02-19
AU8186101A (en) 2002-01-02
JP2004501130A (ja) 2004-01-15
NO329491B1 (no) 2010-10-25
US20100298442A1 (en) 2010-11-25

Similar Documents

Publication Publication Date Title
EA200300040A1 (ru) 1-аминоалкилциклогексаны в качестве антагонистов 5-нт3 и нейрональных никотиновых рецепторов
ATE515513T1 (de) Behandlung von fibrose durch antagonismus zwischen il-13 und il-13-rezeptorketten
ATE403437T1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur behandlung von rheumatoiden arthritis
UA74419C2 (ru) Замещенные пиридины и их применение как антагонистов рецептора метаботропного глутамата
ATE302194T1 (de) Metabotrope glutamatrezeptorantagonisten zur behandlung von krankheiten des zentralen nervensystems
DK1265630T3 (da) Anvendelse af insulin til behandling af brusksygdomme
GEP20022676B (en) 4-Phenyl-Pyridine Derivatives, Method for Their Production and Their Use for Treatment of Disorders Caused by Antagonist of NK-1 Receptors
ATE539768T1 (de) Kombinationen von metabotropische-glutamat- rezeptor-antagonisten und ihre verwendung zur behandlung von suchtstörungen
EA200600294A1 (ru) [1,8] нафтиридин-2-оны и родственные соединения для лечения шизофрении
DE69508093D1 (de) Substituierte piperidine für die behandlung von allergischen krankheiten
EA200300293A1 (ru) Противовоспалительные конденсированные пирролокарбазолы
DE602004027021D1 (de) Cgrp-rezeptorantagonisten
NO990912D0 (no) Terapeutiske kombinasjoner av PAR-antagonister og RXR-antagonister og deres anvendelse
ATE315390T1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
EA200500173A1 (ru) Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
DE60324544D1 (de) Muskarin antagonisten
EA200400734A1 (ru) Способ и композиция для потенциирования действия опиатного анальгетика
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
EA200500803A1 (ru) Антагонисты ccr1 для лечения воспалительных артритов, демиелинизационных воспалительных заболеваний
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
BRPI0412629A (pt) método de tratamento de disfunção ocular em mamìferos
EA200400637A1 (ru) Насыщенные 1-аминоалкилциклогексановые антагонисты nmda, 5-ht3 и нейронных никотиновых рецепторов
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
DK1000046T3 (da) Piperazinderivater, der er aktive på den nedre urinvejskanal

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU